0001654954-19-003959.txt : 20190402 0001654954-19-003959.hdr.sgml : 20190402 20190402143743 ACCESSION NUMBER: 0001654954-19-003959 CONFORMED SUBMISSION TYPE: 15-12G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190402 DATE AS OF CHANGE: 20190402 EFFECTIVENESS DATE: 20190402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medite Cancer Diagnostics, Inc. CENTRAL INDEX KEY: 0000075439 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364296006 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-00935 FILM NUMBER: 19723952 BUSINESS ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 BUSINESS PHONE: 4078490290 MAIL ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 FORMER COMPANY: FORMER CONFORMED NAME: CytoCore Inc DATE OF NAME CHANGE: 20060815 FORMER COMPANY: FORMER CONFORMED NAME: MOLECULAR DIAGNOSTICS INC DATE OF NAME CHANGE: 20011009 FORMER COMPANY: FORMER CONFORMED NAME: AMPERSAND MEDICAL CORP DATE OF NAME CHANGE: 19990527 15-12G/A 1 mdit1512ga.htm 15-12G/A Blueprint
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
 
Amendment No.1
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 
 
 
 
Commission File Number
  
000-00935
 
MEDITE Cancer Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
 
10524 Moss Park Rd. Ste-204-357
Orlando, FL 32832
Telephone: (407) 996-9630
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
 
 
Rule 12g-4(a)(1)
☐
Rule 12g-4(a)(2)
☐
Rule 12h-3(b)(1)(i)
☐
Rule 12h-3(b)(1)(ii)
☒
Rule 15d-6
☐
Rule 15d-22(b)
☐
 
Approximate number of holders of record as of the certification or notice date: 372
 
EXPLANATORY NOTE
 
 
On behalf of MEDITE Cancer Diagnostics, Inc., a Delaware corporation (“Company”), we hereby request that certain Form 15-12G filed on March 22, 2019 (“Form 15), be withdrawn effective immediately. The Company is seeking withdrawal of the Form 15 because upon further review the Company exceeded $10,000,000 in total assets on the last days of the last three (3) consecutive years, respectively, leading up to December 31, 2018, and it is management’s belief that the Company does not qualify for the termination of its reporting obligations under Rule 12h-3(b)(1)(ii). The Company is not currently delinquent on any prior required filings and will resume its reporting obligations immediately. 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this notice to be signed on its behalf by the undersigned hereunto duly authorized person.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDITE Cancer Diagnostics, Inc.
 
 
 
 
 
Date:
 
April 2, 2019
 
 
 
By:
 
/s/ Elmar A. Dave
 
 
 
 
 
 
 
 
Name:
 
Elmar A. Dave
 
 
 
 
 
 
 
 
Title:
 
Chief Executive Officer and President